更新于：2024-09-21
Telithromycin
泰利霉素
更新于：2024-09-21
概要
基本信息
原研机构 |
最高研发阶段临床前 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C43H65N5O10 |
InChIKeyLJVAJPDWBABPEJ-PNUFFHFMSA-N |
CAS号191114-48-4 |
关联
28
项与 泰利霉素 相关的临床试验Steady state telithromycin pharmacokinetics and pharmacodynamic in adult patients with mild-moderate acute exacerbation of chronic obstructive pulmonary disease treated with a standard oral dose 800 mg od for 5 days - TELI AECOPD
Multinational, Randomized, Double-Blind, Double Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 10 Days Penicillin V 13.3 mg/kg Tid in Children 6 Months to Less Than 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis
Multinational, Randomized, Double Blind, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 800 mg od Versus 10 Days Penicillin V 500 mg Tid in Adolescent and Adult Subjects Equal to or Over 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis
100 项与 泰利霉素 相关的临床结果
登录后查看更多信息
100 项与 泰利霉素 相关的转化医学
登录后查看更多信息
100 项与 泰利霉素 相关的专利（医药）
登录后查看更多信息
900
项与 泰利霉素 相关的文献（医药）2024-09-21Journal of biomolecular structure & dynamics
Structure-based drug designing against
Leishmania donovani
using docking and molecular dynamics simulation studies: exploring glutathione synthetase as a drug target
Article
作者: Dubey, Vikash Kumar ; Borkotoky, Subhomoi ; Sarma, Manash
In the pursuit of developing novel anti-leishmanial agents, we conducted an extensive computational study to screen inhibitors from the FDA-approved ZINC database against Leishmania donovani glutathione synthetase. The three-dimensional structure of Leishmania donovani glutathione synthetase was constructed by homology modeling, using the crystallographic structure of Trypanosoma brucei glutathione synthetase as a template. Subsequently, molecular docking studies were carried out for a large number of compounds using AutoDock Vina. Among the screened compounds, we selected the top five with strong binding affinity to Leishmania donovani glutathione synthetase but having a very low affinity to its human homolog. Further investigations on protein-ligand complexes were done by conducting molecular dynamics (MD) simulation and MM/PBSA analysis. The results revealed that Olysio (Simeprevir) exhibited the lowest binding energy (-89.21 kcal/mol), followed by Telithromycin (-45.34 kcal/mol). These findings showed that these compounds have the potential to act as inhibitors of glutathione synthetase. Hence, our study provides valuable insights for the development of a novel therapeutic strategy against Leishmania donovani by targeting the glutathione synthetase enzyme.Communicated by Ramaswamy H. Sarma.
2024-05-01Journal of general internal medicine
Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis
Review
作者: Ebell, Mark H ; Kurotschka, Peter K ; Hulme, Cassie ; Bentivegna, Michelle
BACKGROUND:
The objective of this network meta-analysis was to compare rates of clinical response and mortality for empiric oral antibiotic regimens in adults with mild-moderate community-acquired pneumonia (CAP).
METHODS:
We searched PubMed, Cochrane, and the reference lists of systematic reviews and clinical guidelines. We included randomized trials of adults with radiologically confirmed mild to moderate CAP initially treated orally and reporting clinical cure or mortality. Abstracts and studies were reviewed in parallel for inclusion in the analysis and for data abstraction. We performed separate analyses by antibiotic medications and antibiotic classes and present the results through network diagrams and forest plots sorted by p-scores. We assessed the quality of each study using the Cochrane Risk of Bias framework, as well as global and local inconsistency.
RESULTS:
We identified 24 studies with 9361 patients: six at low risk of bias, six at unclear risk, and 12 at high risk. Nemonoxacin, levofloxacin, and telithromycin were most likely to achieve clinical response (p-score 0.79, 0.71, and 0.69 respectively), while penicillin and amoxicillin were least likely to achieve clinical response. Levofloxacin, nemonoxacin, azithromycin, and amoxicillin-clavulanate were most likely to be associated with lower mortality (p-score 0.85, 0.75, 0.74, and 0.68 respectively). By antibiotic class, quinolones and macrolides were most effective for clinical response (0.71 and 0.70 respectively), with amoxicillin-clavulanate plus macrolides and beta-lactams being less effective (p-score 0.11 and 0.22). Quinolones were most likely to be associated with lower mortality (0.63). All confidence intervals were broad and partially overlapping.
CONCLUSION:
We observed trends toward a better clinical response and lower mortality for quinolones as empiric antibiotics for CAP, but found no conclusive evidence of any antibiotic being clearly more effective than another. More trials are needed to inform guideline recommendations on the most effective antibiotic regimens for outpatients with mild to moderate CAP.
2024-03-01Journal de mycologie medicale
Pythium insidiosum: In vitro oomicidal evaluation of telithromycin and interactions with azithromycin and amorolfine hydrochloride
Article
作者: Maciel, Aline Fontanella ; Ianiski, Lara Baccarin ; Sangioni, Luis Antônio ; Botton, Sônia de Avila ; Pal, Mahendra ; Pereira, Daniela Isabel Brayer ; Colla, Ana Carolina Nolasco ; Braga, Caroline Quintana ; Santurio, Janio Morais
This study evaluated the repositioning of the ketolide antibacterial telithromycin (TLT) against the oomycete Pythium insidiosum and verified the combination of TLT and the antimicrobials azithromycin (AZM) and amorolfine hydrochloride (AMR), which have known anti-P. insidiosum activity. Susceptibility tests of P. insidiosum isolates (n = 20) against the drugs were carried out according to CLSI protocol M38-A2, and their combinations were evaluated using the checkerboard microdilution method. The minimum inhibitory concentrations were 0.5-4 µg/mL for TLT, 2-32 µg/mL for AZM, and 16-64 µg/mL for AMR. For the TLT+AZM combination, 52.75 % of interactions were indifferent, 43.44 % were antagonistic, and 9.70 % were synergistic. As for interactions of the TLT+AMR combination, 60.43 % were indifferent, 39.12 % were antagonistic, and 10.44 % synergistic interactions. This study is the first to evaluate the repositioning of the antibacterial TLT against mammalian pathogenic oomycetes, and our results show that its isolated action is superior to its combinations with either AZM or AMR. Therefore, we recommend including TLT in future research to evaluate therapeutic approaches in different clinical forms of human and animal pythiosis.
100 项与 泰利霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性细菌性鼻窦炎 | 美国 | 2004-04-01 | |
| 感染 | 美国 | 2004-04-01 | |
| 急性鼻窦炎 | 欧盟 | 2001-07-09 | |
| 急性鼻窦炎 | 冰岛 | 2001-07-09 | |
| 急性鼻窦炎 | 列支敦士登 | 2001-07-09 | |
| 急性鼻窦炎 | 挪威 | 2001-07-09 | |
| 慢性支气管炎 | 欧盟 | 2001-07-09 | |
| 慢性支气管炎 | 冰岛 | 2001-07-09 | |
| 慢性支气管炎 | 列支敦士登 | 2001-07-09 | |
| 慢性支气管炎 | 挪威 | 2001-07-09 | |
| 社区获得性肺炎 | 欧盟 | 2001-07-09 | |
| 社区获得性肺炎 | 冰岛 | 2001-07-09 | |
| 社区获得性肺炎 | 列支敦士登 | 2001-07-09 | |
| 社区获得性肺炎 | 挪威 | 2001-07-09 | |
| 咽炎 | 欧盟 | 2001-07-09 | |
| 咽炎 | 冰岛 | 2001-07-09 | |
| 咽炎 | 列支敦士登 | 2001-07-09 | |
| 咽炎 | 挪威 | 2001-07-09 | |
| 扁桃体炎 | 欧盟 | 2001-07-09 | |
| 扁桃体炎 | 冰岛 | 2001-07-09 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 链球菌感染 | 临床3期 | 美国 | 2006-02-01 | |
| 链球菌感染 | 临床3期 | 阿根廷 | 2006-02-01 | |
| 链球菌感染 | 临床3期 | 智利 | 2006-02-01 | |
| 链球菌感染 | 临床3期 | 哥斯达黎加 | 2006-02-01 | |
| 化脓性中耳炎 | 临床3期 | 美国 | 2006-01-01 | |
| 化脓性中耳炎 | 临床3期 | 阿根廷 | 2006-01-01 | |
| 化脓性中耳炎 | 临床3期 | 巴西 | 2006-01-01 | |
| 化脓性中耳炎 | 临床3期 | 加拿大 | 2006-01-01 | |
| 化脓性中耳炎 | 临床3期 | 智利 | 2006-01-01 | |
| 化脓性中耳炎 | 临床3期 | 哥伦比亚 | 2006-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 278 | (醖鏇艱糧範製餘衊蓋積) = 壓簾鹽繭製廠獵廠製鹹 網網選範夢淵簾襯淵鹹 (鹹鏇選鹹憲齋憲構醖醖 ) | - | 2006-04-13 | |||
Placebo | (醖鏇艱糧範製餘衊蓋積) = 鹽糧顧鑰獵鹽鹽觸願衊 網網選範夢淵簾襯淵鹹 (鹹鏇選鹹憲齋憲構醖醖 ) | ||||||
N/A | 734 | Telithromycin 800 mg once daily for 5 days | 憲窪鑰蓋夢獵醖網壓窪(選膚鹽鹽願繭衊夢窪醖) = 齋鏇衊鏇夢淵衊鹽糧艱 艱壓餘願獵鹹築鹹衊廠 (遞積餘淵蓋齋淵築顧艱 ) | - | 2005-03-21 | ||
Comparator (Cefuroxime axetil 250 mg twice daily) | 憲窪鑰蓋夢獵醖網壓窪(選膚鹽鹽願繭衊夢窪醖) = 築鹽艱窪鹽餘餘網淵憲 艱壓餘願獵鹹築鹹衊廠 (遞積餘淵蓋齋淵築顧艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用